Yahoo
NasdaqCM - Delayed Quote USD

InMed Pharmaceuticals Inc. (INM)

15.56 +2.56 (+19.65%)
At close: November 6 at 4:00:01 PM EST
Ticker Change
INM is trading under new symbol MTRI effective Nov. 9, 2026
Chart Range Bar
Loading chart for INM
  • Previous Close 13.01
  • Open 13.71
  • Bid 1.33 x 1000
  • Ask 1.71 x 200
  • Day's Range 13.70 - 16.44
  • 52 Week Range 5.75 - 23.30
  • Volume 27,154
  • Avg. Volume 7,733
  • Market Cap (intraday) 8.548M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -27.60
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

www.inmedpharma.com

6

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INM
46.79%
S&P 500 (^GSPC)
7.76%

1-Year Return

INM
8.74%
S&P 500 (^GSPC)
9.77%

3-Year Return

INM
81.86%
S&P 500 (^GSPC)
68.96%

5-Year Return

INM
99.79%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY24
Revenue 1.6M
Earnings --
Profit Margin 0.00%

Q4

FY23

Q1

FY24

Q2

FY24

Q3

FY24

0
1M
2M
3M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -85.56%

  • Return on Equity (ttm)

    -222.07%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -11.97M

  • Diluted EPS (ttm)

    -27.60

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.13M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -2.73M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: